Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing
- PMID: 12624100
- DOI: 10.1074/jbc.M211596200
Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing
Abstract
Stimulus-induced posttranslational processing of human monocyte interleukin-1beta (IL-1beta) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death. Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs). CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved. Affinity labeling with [(14)C]CRIDs and affinity chromatography on immobilized CRID were used in seeking potential protein targets of their action. Following treatment of intact human monocytes with an epoxide-bearing [(14)C]CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target. Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1beta posttranslational processing. When extracts of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by soluble CRID. Recombinant GST Omega 1-1 readily incorporated [(14)C]CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys(32) to alanine. Peptide mapping by high performance liquid chromatography-mass spectrometry also demonstrated that Cys(32) was the site of modification. Although S-alkylglutathiones did not arrest ATP-induced IL-1beta posttranslational processing or inhibit [(14)C]CRID incorporation into cell-associated GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes. Therefore, the ability of CRIDs to arrest stimulus-induced IL-1beta posttranslational processing may be attributable to their interaction with GST Omega 1-1.
Similar articles
-
Human monocyte interleukin-1beta posttranslational processing. Evidence of a volume-regulated response.J Biol Chem. 1996 Nov 22;271(47):29830-8. doi: 10.1074/jbc.271.47.29830. J Biol Chem. 1996. PMID: 8939922
-
Antimicrobial peptides initiate IL-1 beta posttranslational processing: a novel role beyond innate immunity.J Immunol. 2002 Mar 15;168(6):3024-32. doi: 10.4049/jimmunol.168.6.3024. J Immunol. 2002. PMID: 11884475
-
Human monocyte stimulus-coupled IL-1beta posttranslational processing: modulation via monovalent cations.Am J Physiol. 1998 Dec;275(6):C1538-47. doi: 10.1152/ajpcell.1998.275.6.C1538. Am J Physiol. 1998. PMID: 9843715
-
ATP treatment of human monocytes promotes caspase-1 maturation and externalization.J Biol Chem. 1999 Dec 24;274(52):36944-51. doi: 10.1074/jbc.274.52.36944. J Biol Chem. 1999. PMID: 10601248
-
Characterization of the omega class of glutathione transferases.Methods Enzymol. 2005;401:78-99. doi: 10.1016/S0076-6879(05)01005-0. Methods Enzymol. 2005. PMID: 16399380 Review.
Cited by
-
Synthesis, biological evaluation and molecular modeling studies of novel 1,2,3-triazole-linked menadione-furan derivatives as P2X7 inhibitors.J Bioenerg Biomembr. 2022 Dec;54(5-6):227-239. doi: 10.1007/s10863-022-09947-2. Epub 2022 Sep 7. J Bioenerg Biomembr. 2022. PMID: 36070071
-
Molecular Characteristics of Cell Pyroptosis and Its Inhibitors: A Review of Activation, Regulation, and Inhibitors.Int J Mol Sci. 2022 Dec 17;23(24):16115. doi: 10.3390/ijms232416115. Int J Mol Sci. 2022. PMID: 36555757 Free PMC article. Review.
-
A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation.Br J Pharmacol. 2023 Aug;180(15):1930-1948. doi: 10.1111/bph.16058. Epub 2023 Feb 28. Br J Pharmacol. 2023. PMID: 36788033 Free PMC article.
-
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.ACS Med Chem Lett. 2022 Aug 1;13(8):1321-1328. doi: 10.1021/acsmedchemlett.2c00242. eCollection 2022 Aug 11. ACS Med Chem Lett. 2022. PMID: 35978696 Free PMC article.
-
Inflammasome inhibitors: promising therapeutic approaches against cancer.J Hematol Oncol. 2019 Jun 26;12(1):64. doi: 10.1186/s13045-019-0755-0. J Hematol Oncol. 2019. PMID: 31242947 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials